RGT-419B

· Regor Pharmaceuticals Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for RGT-419B, covering 2025-01-20 to 2026-04-02. Get the full timeline:

Most recent: Clinical Trial Update: FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer [Phase 1]

See pricing